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Summary
 
Tumor necrosis factor (TNF) signaling leads to pleiotropic responses in a wide range of cell
types, in part by activating antiapoptotic and proapoptotic signaling pathways. Thus, although
TNF can cause apoptosis and may prove useful in the treatment of malignancies, most cells are
resistant to TNF-induced cell death unless de novo protein synthesis is inhibited. Previous
studies suggested that TNF activation of the nuclear factor (NF)-
 
k
 
B transcription factor family
 
antagonizes the proapoptotic signals initiated by TNF-
 
a
 
.
 
 TNF receptor–associated factor
(TRAF)2 has also been shown to mediate crucial antiapoptotic signals during TNF stimulation,
yet is not essential in activation of NF-
 
k
 
B under physiologic conditions, thus raising questions
about the relationship between these antiapoptotic pathways. We report here that inhibition of
TRAF2 and NF-
 
k
 
B function in primary cells, by coexpression of a constitutive repressor of
multiple NF-
 
k
 
B/Rel proteins (I
 
k
 
B
 
a
 
.DN) and a dominant negative form of TRAF2
(TRAF2.DN), synergistically enhanced TNF-induced apoptosis. The effects were stimulus de-
pendent, such that neither inhibitory molecule affected Fas- and daunorubicin-induced apop-
tosis to the same degree as TNF-induced death. These findings indicate that the NF-
 
k
 
B and
TRAF2 pathways activate independent antiapoptotic mechanisms which act in concert to sup-
press the proapoptotic signals induced by TNF-
 
a
 
.
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O
 
ligomerization of TNFR1 by TNF-
 
a
 
 results in mul-
tiple intracellular changes, including activation of the
transcription factor nuclear factor (NF)-
 
k
 
B, the c-Jun
NH
 
2
 
-terminal kinase (JNK), and apoptosis (1). These
events are initiated by the TNF-dependent recruitment of
the adapter molecule TNFR death domain–associated pro-
tein (TRADD) to the TNFR1 complex (2, 3). Previous
studies suggested that TNFR1–induced apoptosis and
proinflammatory responses (such as those mediated by NF-
 
k
 
B and JNK activation) are mutually exclusive and are ini-
tiated by separate downstream components of the TNFR
signal transduction machinery (3, 4). Recent experiments
have provided support for this paradigm by demonstrating
that the proinflammatory signaling initiated by TNFR1 is
closely linked to protection against apoptosis. Specifically,
JNK activation by TNF requires the signal adapter TNFR-
associated factor (TRAF)2 but not the adapter receptor-
interacting protein (RIP), whereas TNF-induced NF-
 
k
 
B
activation requires the adapter RIP but not TRAF2 (5–8).
Each of these signal transducers also appears to initiate anti-
apoptotic signals that inhibit cell death during TNF stimu-
lation. For example, it was recently shown that inhibition
of the TRAF2 signaling pathway, either by overexpression
of a dominant negative TRAF2 (TRAF2.DN) or by gene
targeting and inactivation, enhanced TNF-induced apop-
tosis of normal murine lymphocytes or fibroblasts (5, 6). In
other studies, NF-
 
k
 
B inactivation enhanced the sensitivity
of cultured cell lines and embryonic fibroblasts to TNF-
induced apoptosis (4, 9–11). However, the relationship be-
tween these pathways and whether they converge on the
same antiapoptotic effector molecules are not known.
Since TNF-
 
a
 
 triggers TRAF2/JNK and NF-
 
k
 
B activa-
tion by independent signaling pathways, it was thought that
TRAF2- and NF-
 
k
 
B–mediated pathways provide inde-
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k
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pendent, nonoverlapping antiapoptotic signals that were
not expected to interact with each other during TNF-
induced apoptosis. In contrast to this current paradigm, we
show in this study that TRAF2- and NF-
 
k
 
B–mediated sig-
nals play synergistic roles in preventing TNF-induced apop-
tosis.
 
Materials and Methods
 
Transgenic Mice.
 
Transgenic mice expressing I
 
k
 
B
 
a
 
.DN or
TRAF2.DN were described previously (5, 12).
 
Kinase and NF-
 
k
 
B Assays.
 
In vitro JNK assays were done as
described previously (5). In brief, 2–5 
 
3 
 
10
 
6
 
 cells were treated
with medium alone or rMu–TNF-
 
a
 
 (R&D Systems, Inc., Min-
neapolis, MN) and lysed. For the kinase reaction, 1.5–3.0 
 
m
 
g of
purified glutathione 
 
S
 
-transferase (GST)–c-Jun(1-79) (a gift from
Dr. H. Hanafusa, The Rockefeller University), 0.5 
 
m
 
Ci of [
 
g
 
-
 
32
 
P]
ATP and ATP (20 
 
m
 
M) was incubated with the immunoprecipi-
tated JNK in a total volume of 30 
 
m
 
l of JNK reaction buffer for
20 min at 30
 
8
 
C. The reactions were stopped with 2
 
3
 
 loading
buffer, boiled for 5 min, and run on a 12% SDS-PAGE gel. To
measure NF-
 
k
 
B activation, nuclear extracts prepared from thy-
mocyte lysates stimulated with medium alone or TNF were used
for gel-shift assays as outlined previously (5).
 
Cell Killing Assay.
 
For thymocyte apoptosis assays, freshly
isolated thymocytes (2 
 
3 
 
10
 
5
 
 cells/well) were treated with the in-
dicated amounts of rMu–TNF-
 
a
 
 (R&D Systems, Inc.), or anti–
Mu-Fas mAb (Jo2; PharMingen, San Diego, CA) for 22 h in the
presence or absence of 30 
 
m
 
g/ml cycloheximide (CHX; Sigma
Chemical Co., St. Louis, MO), with anti-CD3 (10 
 
m
 
g/ml) and anti-
CD28 antibody (10 
 
m
 
g/ml), or with the indicated amounts of
daunorubicin. Viable cells were quantified for 30 s at a constant
rate by flow cytometry after staining with 5 
 
m
 
g/ml propidium
iodide (PI) as described previously (5, 13). Specific cell death (%)
was determined from the percentages of viable (PI-negative) cells
and was calculated as 100 
 
3 
 
(1 
 
2 
 
no. of viable cells in a treated
sample/no. of viable cells in the control).
 
Results and Discussion
 
To determine the relationship between TRAF2- and
NF-
 
k
 
B–dependent antiapoptotic signaling pathways during
TNF stimulation of normal cells, we have tested the role of
these proteins in the TNF-induced apoptosis of thymocytes
from transgenic mice expressing 
 
trans
 
-dominant repressors
of I
 
k
 
B
 
a
 
 (I
 
k
 
B
 
a
 
.DN [12]) and/or TRAF2 (TRAF2.DN
[5]). Expression of I
 
k
 
B
 
a
 
.DN, which lacks sequences re-
quired for signal-dependent degradation and functions as a
constitutive repressor of multiple NF-
 
k
 
B/Rel proteins
(14), abolished the activation of NF-
 
k
 
B, but not JNK, in
thymocytes upon TNF stimulation (Fig. 1). As reported
previously (5), expression of TRAF2.DN, which lacks the
NH
 
2
 
-terminal RING and zinc finger domains, impaired
the activation of JNK by TNF, but not that of NF-
 
k
 
B.
These results show that the activation of JNK and NF-
 
k
 
B
by TNF in thymocytes is mediated by two discrete signaling
pathways (Fig. 1). When both I
 
k
 
B
 
a
 
.DN and TRAF2.DN
were expressed, the activation of NF-
 
k
 
B and JNK by TNF
were both severely impaired (Fig. 1).
To determine the relationship between the NF-
 
k
 
B
and TRAF2 pathways in normal cells, we measured TNF-
 
a
 
–induced death using thymocytes. Cells from control
mice were relatively resistant to TNF-induced apoptosis,
which could be enhanced to a modest degree by treatment
with CHX to prevent new protein synthesis (Fig. 2, 
 
a 
 
and
 
b
 
). Inhibition of TRAF2 by TRAF2.DN expression poten-
tiated the TNF-induced apoptosis of thymocytes, and this
level of killing could be further increased by CHX treat-
ment, suggesting that TNF retained the ability to induce
synthesis of antiapoptotic proteins despite the observed im-
pairment of JNK activation (Fig. 2, 
 
a 
 
and 
 
b
 
). To determine
whether NF-
 
k
 
B activation suppresses the TNF-induced
apoptosis of normal T lymphoid cells, thymocytes from
I
 
k
 
B
 
a
 
.DN mice were treated with increasing concentra-
Figure 1. TNF-induced JNK and
NF-kB activation are mediated by dis-
tinct signal transduction pathways. (Top)
Cell lysates prepared from thymocytes
unstimulated (2) or stimulated (1) with
TNF (10 ng/ml) for 2.5 min were used
to measure JNK activity by immuno-
complex kinase assay with GST–c-Jun(1-
79) as a substrate. (Bottom) Nuclear ex-
tracts (4 mg) prepared from thymocytes
unstimulated (2) or stimulated (1) with
TNF for 15 min were used in gel-shift
assays of NF-kB/Rel binding activity.
Figure 2. Inhibition of TRAF2 and NF-kB activity synergistically sen-
sitizes thymocytes to TNF-induced apoptosis. (a) Thymocytes (2 3 105/
well) from the indicated mice (6–8 wk old) were treated for 22 h with in-
creasing amounts of murine TNF-a as indicated, and the percentages of
cell death are shown as mean 6 SD of triplicate samples from each group.
Similar results were also obtained with human TNF-a (data not shown),
which is specific for murine TNFR1. Representative data from one of
five experiments are shown. Of note, the number and distribution of the
major thymic subsets were normal, with the exception of a previously re-
ported decrease in single positive cells in IkBa.DN-expressing mice and
in double-TG mice expressing both TRAF2.DN and IkBa.DN (data not
shown); however, this subset represented ,1% of thymocytes in wild-
type littermates. (b) Thymocytes from the indicated mice were treated
overnight with TNF (33 ng/ml), with or without CHX (30 mg/ml), as
indicated. Background cell death of thymocytes in medium 6 CHX
alone was z20–30%. Mean (6 SD) data from one of three experiments,
all of which yielded similar results, are shown.1383 Lee et al. Brief Definitive Report
tions of TNF. Inhibition of NF-kB activation by overex-
pression of IkBa.DN significantly enhanced TNF-induced
apoptosis of thymocytes (Fig. 2 a). Of note, CHX treat-
ment of thymocytes from IkBa.DN mice led to no further
enhancement in their TNF-induced apoptosis, suggesting
that the effect of CHX on TNF-induced apoptosis is medi-
ated mostly through inhibition of the synthesis of NF-kB–
dependent antiapoptotic proteins (Fig. 2, a and b).
Strikingly, when thymocytes from IkBa.DN 3 TRAF2.
DN double-transgenic (TG) mice were treated with in-
creasing concentrations of TNF-a, they were at least 1,000
times more sensitive to TNF-induced apoptosis than cells
from normal mice, and at least 100 times more sensitive
than those from either IkBa.DN or TRAF2.DN TG mice
(Fig. 2 a). These results indicate that NF-kB– and TRAF2-
dependent antiapoptotic signals synergistically protect cells
from TNF-induced apoptosis. Moreover, treatment of
thymocytes from IkBa.DN 3 TRAF2.DN double-TG
mice with TNF-a induced a level of apoptosis similar to
that induced by TNF in CHX-treated thymocytes from
TRAF2.DN single-TG mice (Fig. 2 b). This finding fur-
ther supports the conclusion that the principal effect of
CHX is to inhibit de novo synthesis of antiapoptotic pro-
teins that are regulated by the state of NF-kB activation.
Fas death domain–associated protein (FADD), an effec-
tor of TNF-induced apoptosis recruited by heterotypic
death domain interactions with TRADD, is also an effector
of apoptosis induced by the Fas receptor (3, 15, 16). More-
over, NF-kB signaling occurs in thymocytes in situ (17,
18), suggesting that the activation state of NF-kB could in-
fluence Fas-induced apoptosis. To investigate this possibil-
ity, thymocytes from the four sets of mice were cultured in
the presence of increasing concentrations of a cross-linking
anti-Fas antibody (Fig. 3 a). Compared with the dramatic
increase in TNF-induced apoptosis caused by simultaneous
inhibition of TRAF2 and NF-kB activation, increased sen-
sitivity to Fas-induced apoptosis was minimal. In addition,
when CD41CD81 thymocytes were activated by anti-
CD3 and anti-CD28 antibodies, physiological stimuli in-
volved in thymocyte selection, the induction of apoptosis in
these cells was not affected by IkBa.DN and TRAF2.DN
expression (Fig. 3 b). TRADD and the NF-kB signaling
pathway have also been implicated in the apoptosis induced
by interactions between TNF-related apoptosis–inducing
ligand (TRAIL) and death receptors (DR4, DR5 [19, 20]).
However, TRAIL did not induce any significant cell death
in wild-type thymocytes or in thymocytes from transgenic
mice expressing TRAF2.DN and IkBa.DN (data not
shown). Finally, NF-kB activation has been suggested to
play a role in the induction of apoptosis of some tumor
cells by cancer chemotherapeutic compounds such as
daunorubicin (11), a finding offering the hope of potential
therapeutic benefits. The therapeutic window for such ef-
fects would be more favorable if they were restricted to
cancer cells and did not affect primary cells. Importantly,
then, neither TRAF2 nor NF-kB activation played any
role during daunorubicin-induced apoptosis of thymocytes
(Fig. 3 c). Therefore, these results suggest that in nonneo-
plastic cells, the antiapoptotic role of TRAF2 and NF-kB
may be restricted to the context of TNF signaling.
As shown in this study and in previous reports (5, 6, 8),
TNF-induced JNK and NF-kB activation appear to be
triggered by independent signaling pathways, with the
former but not the latter mediated by TRAF2. In addition,
NF-kB–mediated antiapoptosis required de novo protein
synthesis, whereas TRAF2-mediated antiapoptosis did not.
Therefore, it was surprising to see that TRAF2 and NF-kB
played synergistic roles in preventing TNF-induced apop-
tosis. How might this happen? One possibility is that
Figure 3. Inhibition of TRAF2 and NF-kB activity does not affect the sensitivity of thymocytes to apoptosis induced by other stimuli. Thymocytes
(2 3 105/well) from the indicated mice were treated for 22 h with (a) anti-Fas antibody (Jo2); (b) anti-CD3 and anti-CD28 antibodies; or (c) daunorubicin.
Mean (6 SD) data from one of three experiments with similar results are shown.
Figure 4. Models for anti-
apoptotic synergism induced by
TNF-a.1384 Antiapoptosis by TRAF2 and NF-kB
TRAF2- and NF-kB–mediated pathways reconverge at
some point to effect antiapoptosis during TNF stimulation
(Fig. 4 a); for instance, TRAF2 may be responsible for re-
cruitment of an antiapoptotic protein whose basal level of
expression is induced by TNF-a in an NF-kB–dependent,
JNK-independent manner. Alternatively, TRAF2/JNK
and NF-kB activation could lead to the independent inhi-
bition of discrete apoptotic effectors whose synergistic ac-
tion is required for efficient induction of apoptosis (Fig. 4 b).
Although TNF was identified by its ability to kill various
tumor cells, most cells do not undergo apoptosis in response
to TNF. Our results indicate that two distinct antiapoptotic
signals are generated by TNF stimulation, and that removal
of either one is insufficient to allow efficient apoptosis in-
duction by TNF. Thus, the combined inhibition of both
antiapoptotic pathways during TNF stimulation may en-
hance the efficacy of TNF-based antineoplastic therapies.
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